JCC: Analysis of the effectiveness and safety of Ustekinumab in ulcerative colitis

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and medsci.

Although traditional treatment drugs can improve symptoms, they cannot prevent the underlying inflammatory process.

UTI slave monoclonal antibody (Ustekinumab) is the world's first fully human "dual targeting" IL-12 and IL-23 inhibitor, received US Food and Drug Administration as early as in 2008 Management Board ( the FDA ) approved for the treatment of psoriasis It was approved for the treatment of active CD in 2016, and the CD indication was approved in China in March 2020.

The researchers prospectively included patients in the ENEIDA registry into this study.

A total of 95 patients were included in this study.

Figure: Changes in the efficacy of Ulsinumumab in the treatment of ulcerative colitis

This study confirms that Ustekinumab has a good effect on alleviating disease activity in real life, both in the short and long term, but a higher burden of inflammation at baseline is associated with a lower probability of remission.

Original source:

María Chaparro.